drugset / Trial / NCT06205056

Summary

This is a Phase I, randomized, double-blind, placebo-controlled clinical study to define the safety and immunogenicity resulting from a rapid dose-escalating vaccination schedule as compared to that of a co-administered, dose-consistent vaccination schedule. Participants randomized to receive vaccines will get either dose-consistent injections of CH505 TF chTrimer+ALFQ co-administered with Ad26.Mos4.HIV or rapid, dose-escalating injections of CH505 TF chTrimer+ALFQ with an Ad26.Mos4.HIV prime, followed by dose-consistent injection of CH505 TF chTrimer+ALFQ co-administered with Ad26.Mos4.HIV

Timeline

Start
2024-01-30
Primary completion
2025-12
Completion
2026-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ad26.Mos4.HIV Vaccine 5e+10 unknown Intramuscular
Subject CH505 TF chTrimer Vaccine 300 ug Intramuscular
Background ALFQ Unknown Intramuscular